ADHD Candidate Drug Did Not Meet Primary Endpoint
The drug failed to demonstrate a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).
One of Alcobra’s candidate medications for attention deficit hyperactivity disorder, Metadoxine Extended Release, or MDX, did not meet the primary endpoint in a study analysis, according to a statement from the company.
The analysis reflected data on 283 adult patients enrolled in the phase 3 MEASURE clinical trial. The drug failed to demonstrate a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).
"We are exceedingly disappointed with these top-line results," stated Dr. Yaron Daniely, President and CEO of Alcobra in a prepared statement. "We wish to reiterate our sincere appreciation to all of the patients, investigators, and others who aided us in conducting this study."
